Date：27 July (Thursday)
Time：14:00 – 15:30 (GMT+8)
President, CEO & Chairman
Dr. Roger J. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University (1978) and his M.D. at The Johns Hopkins School of Medicine (1982). He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School (1982 -1988), and was selected and served as the Chief Medical Resident at M.G.H (1988). His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (M.I.T.), in the laboratory of Nobel Laureate, Dr. David Baltimore (1988 -1990). Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was an endowed, tenured Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School in Philadelphia (1990 - 2005). Dr. Pomerantz has published over 300 articles in the scientific literature and presented well over 300 invited lectures, nationally and internationally, concentrating on the clinical research, molecular pathogenesis and especially latency of human immunodeficiency virus (HIV) and other pathogenic human viruses. He was one of the first scientists to study HIV molecular pathogenesis, latency, restricted replication and eradication in vitro and in vivo, and is an internationally recognized expert in these fields. Dr. Pomerantz has been awarded numerous National Institutes of Health (N.I.H.) grants and was continuously funded by the N.I.H. over several decades. He has served as an invited full-time member and then as the Chairman of the Antiviral Advisory Panel for the U.S. Food and Drug Administration (F.D.A.), and on numerous invited N.I.H. advisory commissions, panels, study sections and committees. He was selected to serve on the NIH "Levine Panel", which was tasked, by the President of the United States, with recommending changes to the national scientific and medical agenda, strategy and goals for HIV/AIDS research. Dr. Pomerantz has also been invited to lecture on and discuss key national infectious disease issues at the White House Office of Science and Technology and before the US Senate. His awards and honors have included election as a Fellow to the American Association of Physicians (F.A.A.P.), the American Society of Clinical Investigation (F.A.S.C.I.), the American College of Physicians (F.A.C.P.), the Infectious Diseases Society of America (F.I.D.S.A.), the American Academy of Microbiology (F.A.A.M.) and receiving the President’s Award of the International Society of Neurovirology. Dr. Pomerantz is also an invited member of the Board of Trustees and the Board of Advisors of the Johns Hopkins Business School.
New modalities in biotech have changed the world (eg. PD1 and mRNA vaccines). But they also have great risk in development with many initial failures until clinical full success. How do you balance these and how should investors view their risks and benefits?